Who are GSK2118436's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): REGORAFENIB, Vemurafenib (VEM), vemurafenib + HD IL-2, Tunlametinib plus Vemurafenib, Encorafenib and Binimetinib.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gsk2118436.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

GSK2118436 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

GSK2118436 (GSK2118436) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: BRAF inhibitor. Area: Oncology.

phase 3 BRAF inhibitor BRAF V600E Oncology Small molecule Live · refreshed every 30 min

Target snapshot

GSK2118436 (GSK2118436) — M.D. Anderson Cancer Center. GSK2118436 is a BRAF V600E inhibitor that blocks mutant BRAF kinase signaling in melanoma cells.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
GSK2118436 TARGET	GSK2118436	M.D. Anderson Cancer Center	phase 3	BRAF inhibitor	BRAF V600E
REGORAFENIB	REGORAFENIB		marketed		RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAF V600E, SAPK2, PTK5, Abl, CSF1R	2012-01-01
Vemurafenib (VEM)	Vemurafenib (VEM)	Abramson Cancer Center at Penn Medicine	marketed	BRAF inhibitor	BRAF V600E
vemurafenib + HD IL-2	vemurafenib + HD IL-2	Clinigen, Inc.	marketed	BRAF inhibitor + cytokine immunotherapy	BRAF V600E kinase; IL-2 receptor
Tunlametinib plus Vemurafenib	Tunlametinib plus Vemurafenib	Shanghai Kechow Pharma, Inc.	phase 3	BRAF inhibitor + MEK inhibitor combination	BRAF V600E and MEK1/2
Encorafenib and Binimetinib	Encorafenib and Binimetinib	Pierre Fabre Medicament	phase 3	BRAF inhibitor + MEK inhibitor combination	BRAF V600E/K and MEK1/2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (BRAF inhibitor class)

Abramson Cancer Center at Penn Medicine · 1 drug in this class
M.D. Anderson Cancer Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GSK2118436 — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk2118436. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing